Thursday, May 31, 2012
Repros Therapeutics Inc., of The Woodlands, Texas, said the FDA advised the firm it must complete an integrated safety analysis of completed studies of oral Proellex and submit a report for review prior to any additional trials testing oral administration of telapristone acetate, Proellex's active ingredient.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.